An exploratory analysis of biomarkers of perihematomal edema in the CN-105 in participants with acute supratentorial intracerebral hemorrhage (CATCH) trial

• Published in: Journal of stroke and cerebrovascular diseases 2022-08, Vol.31 (8), p.106600-106600, Article 106600
• Main Authors: Lusk, Jay B., Troy, Jesse, Nowacki, Nathaniel, Kranz, Peter G., Maughan, Maureen, Laskowitz, Daniel T., James, Michael L.
• Format: Article
• Language: English
• Subjects: Intracerebral hemorrhage; Neuroinflammation; Perihematomal edema; Secondary tissue injury
• ISSN: 1052-3057; 1532-8511
• DOI: 10.1016/j.jstrokecerebrovasdis.2022.106600

•Neuroinflammatory biomarkers may predict perihematomal edema volumes in human ICH.•Longitudinal biomarkers show time-sensitive nature of serum proteins and edema volume.•Radiographic and serologic neuroinflammatory biomarkers may catalyze ICH treatments. To identify biomarkers with potential to indicate severity of perihematomal edema and secondary tissue injury after intracerebral hemorrhage (ICH), and which could be used as surrogate markers in future clinical trials for novel ICH therapeutics. This exploratory cohort study compared trends in neuroinflammatory biomarker levels in 18 consecutively enrolled patients with acute supratentorial ICH and 16 patients treated with the investigational neuroprotective therapy CN-105 to identify a panel of 10 biomarkers. Biomarker levels over five days post-hemorrhage were then compared with edema volumes in a larger sample of patients treated with CN-105. Mean normalized edema volumes increased over time; higher CRP levels were associated with increased edema volumes (p = 0.006, r = 0.56). Higher IL8, IL10, MCP, and MMP-9 levels were associated with decreased edema volumes (p = 0.005, r =-0.57; p = 0.02, r =-0.51; p = 0.02, r =-0.52; p = .002, r =-0.63, respectively). IL1-RA, IL1-B, IL23, vWF, and IL17 levels were not significantly associated with edema volumes (p > 0.05). This exploratory study provides some of the first insights into the longitudinal associations between markers of neuroinflammation and development of perihematomal edema and secondary tissue injury in human ICH. We hypothesize that these biomarkers could be used as surrogates for treatment effect in novel therapies intended to limit neuroinflammation after ICH.